Climb Bio Stock Today
| CLYM Stock | 5.44 0.79 16.99% |
PerformanceSolid
| Odds Of DistressFair
|
Climb Bio is selling at 5.44 as of the 8th of February 2026; that is 16.99 percent increase since the beginning of the trading day. The stock's lowest day price was 4.7. Climb Bio has 46 percent odds of going through some form of financial distress in the next two years but had a very solid returns during the last 90 days. The performance scores are derived for the period starting the 10th of November 2025 and ending today, the 8th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 10th of August 2021 | Category Healthcare | Classification Health Care |
Climb Bio is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 47.74 M outstanding shares of which 1.8 M shares are currently shorted by private and institutional investors with about 0.8 trading days to cover. More on Climb Bio
Moving together with Climb Stock
Moving against Climb Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Climb Stock Highlights
| President CEO | BAO BCh | |||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||
Debt LevelsClimb Bio utilizes debt financing to potentially enhance returns on invested capital. The relationship between total debt and total assets provides valuable insight into Climb Bio's leverage profile, showing how much of Climb Bio's resources are funded through borrowing.
| ||||||||||||||||||||||||||||||||||||
Climb Bio (CLYM) is traded on NASDAQ Exchange in USA and employs 17 people. Climb Bio is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 370.92 M. Climb Bio conducts business under Biotechnology sector and is part of Health Care industry. The entity has 47.74 M outstanding shares of which 1.8 M shares are currently shorted by private and institutional investors with about 0.8 trading days to cover.
Climb Bio generates negative cash flow from operations
Check Climb Bio Probability Of Bankruptcy
Ownership AllocationClimb Bio holds a total of 47.74 Million outstanding shares. 30% of Climb Bio outstanding shares are owned by other corporate entities. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Climb Ownership Details
Climb Bio Historical Income Statement
Climb Stock Against Markets
Climb Bio Corporate Management
| Chandra JD | VP Counsel | Profile | |
| Susan MBA | Chief Officer | Profile | |
| Jo PalmerPhillips | Chief Officer | Profile | |
| Emily CPA | Senior Officer | Profile | |
| Cindy MBA | Senior Finance | Profile | |
| Emily Pimblett | Chief Officer | Profile | |
| Nishi MD | Senior Development | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Climb Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in producer price index. To learn how to invest in Climb Stock, please use our How to Invest in Climb Bio guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Will Biotechnology sector continue expanding? Could Climb diversify its offerings? Factors like these will boost the valuation of Climb Bio. Projected growth potential of Climb fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Climb Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
The market value of Climb Bio is measured differently than its book value, which is the value of Climb that is recorded on the company's balance sheet. Investors also form their own opinion of Climb Bio's value that differs from its market value or its book value, called intrinsic value, which is Climb Bio's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Climb Bio's market value can be influenced by many factors that don't directly affect Climb Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Climb Bio's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Climb Bio should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Climb Bio's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.